Press Release
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, CHINA – China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus (“RABV”), which is consistent with the recommendations of the World Health Organization (“WHO”) for a “cocktail” therapeutic paradigm. It demonstrates broad neutralization, which can effectively neutralize different viral strains or genotypes of RABV, providing immediate protection. Moreover, it is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. In addition, the Product can be manufactured at scale with standardized processes and controlled production cost, and also carries no risks of blood-borne infections, low immunogenicity, and minimal interference with vaccine-induced active immunization. The market for rabies passive immunization is substantial, yet existing passive immunization products are constrained by low market penetration and limitations in safety and accessibility. The approval of the Product will provide a new treatment option for patients requiring urgent post-exposure management against rabies in China.
The approval of Silevimig Injection expands the Group’s commercialized innovative drug portfolio to 8 products, with 6 more innovative drugs under marketing review and approximately 20 projects advancing clinical development, further strengthening a tiered innovation pipeline. As of now, CMS’s innovation transformation strategy has fully entered the value-harvesting phase. Leveraging the Group’s existing expert network and market resources, the commercialization rollout of Silevimig Injection is expected to proceed steadily providing sustained momentum to the Group’s performance growth.
About Rabies
Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms, and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage[1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with Category II exposure involving severe immunodeficiency should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary approved passive immunization option in China is human rabies immune globulin (“HRIG”). However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.
More information about Silevimig Injection
Silevimig Injection is a recombinant, fully human bispecific antibody against rabies virus. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and III. Through this mechanism, Silevimig Injection specifically neutralizes the RABV prior to the establishment of full protection by active rabies vaccination.
In a Phase III clinical trial in adults, the Product met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The study confirmed that the Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.
In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd.. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf
2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7): 668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.004
3. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Terrance Bradford Tampa, FL Explains Why Problem-Solving Is One of Construction’s Most Valuable Skills
San Francisco, CA, 18th July 2026, ZEX PR WIRE, Construction projects rarely unfold exactly as planned. Weather conditions, material availability, scheduling conflicts, and unexpected site conditions can all create obstacles that require quick thinking and practical solutions. According to Terrance Bradford Tampa, FL, one of the most valuable skills a construction professional can develop is the ability to solve problems effectively while keeping projects moving forward.
With more than two decades of experience in the construction industry, Bradford has learned that successful projects are not defined by the absence of challenges, but by how those challenges are managed. Every project presents opportunities to adapt, communicate, and make informed decisions that keep work progressing efficiently.
“Every construction project will encounter obstacles at some point,” Bradford says. “The difference is how teams respond. Strong problem-solving keeps projects moving instead of allowing setbacks to become larger issues.”
Every Project Presents Unique Challenges
According to Terrance Bradford Tampa, FL, no two construction projects are exactly alike. Site conditions, client goals, environmental factors, and scheduling demands all introduce different variables that require thoughtful planning and flexibility.
Rather than relying on the same solution every time, Bradford believes construction professionals should evaluate each situation individually and make decisions based on the project’s specific needs.
“Experience gives you perspective,” he explains. “The more projects you complete, the better you become at recognizing potential challenges and identifying practical solutions.”
Communication Improves Problem-Solving
Bradford believes effective communication is one of the most important tools when resolving issues during construction.
Construction projects involve multiple stakeholders, and keeping everyone informed allows decisions to be made more efficiently. Open communication also helps prevent misunderstandings that could create additional delays.
“When everyone understands what’s happening, teams can work together toward a solution much faster,” Bradford says. “Communication reduces uncertainty and helps maintain momentum.”
By encouraging transparency, project teams can respond more confidently when unexpected situations arise.
Staying Calm Under Pressure
Construction can be a fast-paced environment where decisions often need to be made quickly. Bradford believes remaining calm during difficult situations allows leaders to evaluate options more effectively.
“When challenges happen, people naturally look for direction,” he says. “Remaining focused instead of reacting emotionally helps everyone make better decisions.”
This steady approach not only improves project outcomes but also builds confidence throughout the team.
Learning From Every Challenge
One of Terrance Bradford’s guiding principles is viewing challenges as opportunities for growth.
Every project provides lessons that can improve future planning, communication, and decision-making. By reflecting on both successes and setbacks, construction professionals continue strengthening their ability to solve problems more effectively.
“I’ve learned something from every project I’ve worked on,” Bradford explains. “Those experiences help prepare you for the next challenge.”
Continuous improvement allows professionals to develop greater confidence while improving overall project performance.
Preparation Makes a Difference
While unexpected situations cannot always be avoided, Terrance Bradford Tampa, FL believes preparation significantly reduces their impact.
Careful planning, organized documentation, realistic scheduling, and proactive communication help teams anticipate many common challenges before construction begins.
“The more prepared you are, the more options you have when something unexpected occurs,” Bradford says. “Preparation gives teams flexibility.”
Strong preparation also allows projects to remain focused on long-term objectives instead of reacting to every short-term obstacle.
Building Stronger Construction Teams
Bradford believes problem-solving is ultimately a team effort. Encouraging collaboration and creating an environment where individuals feel comfortable sharing ideas often leads to better solutions.
“No single person has every answer,” he explains. “When people work together and bring different perspectives, they’re able to solve problems more effectively.”
Creating a collaborative culture strengthens not only project outcomes but also long-term professional relationships.
Looking Ahead
As construction projects continue becoming more complex, Terrance Bradford Tampa, FL believes problem-solving will remain one of the industry’s most valuable skills. Professionals who combine preparation, communication, adaptability, and collaboration are better equipped to navigate challenges while delivering successful results.
For Bradford, construction has always been about more than building structures. It is about bringing people together, overcoming obstacles, and continuously finding better ways to serve clients and strengthen communities. By approaching every challenge with a solutions-focused mindset, he believes construction professionals can continue delivering quality work while building trust that lasts well beyond project completion.
To learn more visit: https://terrancebradfordtampa.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Numerai Completes Third Strategic NMR Buyback, Bringing Total Repurchases to $3.2 Million
San Francisco, CA, July 17th, 2026, Chainwire
Crowdsourced Hedge Fund Completes Third Open-Market Purchase as Contributor Network and Assets Continue to Grow
Numerai, the decentralized hedge fund powered by crowdsourced machine learning, today announced the completion of a third strategic purchase of Numeraire (NMR), acquiring an additional $1.2 million of the token from the open market. The purchase brings Numerai’s total NMR buybacks to $3.2 million within one year.
The buyback reflects Numerai’s continued investment in the staking system that aligns thousands of independent data scientists toward improving the firm’s Stake-Weighted Meta Model, the machine learning model that powers Numerai’s hedge fund. Contributors stake NMR on their models, earning additional NMR when their predictions perform well on future market data and losing it when they do not. The resulting Stake-Weighted Meta Model continues to outperform Numerai’s internal benchmark models, demonstrating the value of aligning incentives with predictive performance.
Since announcing its first strategic buyback in July 2025, Numerai’s network has expanded significantly. Active accounts have more than doubled over the past year, submissions continue to increase, and the platform has introduced new infrastructure including Numerai Skills, Numerai Model Context Protocol (MCP), and Atomic Blockchain Staking, enabling increasingly autonomous participation by AI systems.
The underlying hedge fund has also continued to grow. According to the company, Numerai now manages approximately $700 million in assets, up from approximately $560 million at the end of 2025.
Numeraire is a fixed-supply Ethereum token capped at 11 million NMR. Because tournament rewards and staking incentives are distributed from Numerai’s treasury, the company is replenishing its holdings through open-market purchases. Before this buyback, approximately 3.1 million NMR remained in Numerai’s treasury.
Unlike the previous two announcements, this buyback had already been completed before today’s announcement. As with prior purchases, the transaction was executed on the open market through Coinbase Institutional at or near the bid price over several weeks to minimize market impact.
Past performance is not indicative of future results. This content does not represent an offer to purchase or sell any security or the interests of any account managed by Numerai GP, LLC or its affiliates. Such an offer may only be made to persons who qualify to invest and in jurisdictions in which such an offer is legal.
About Numerai
Numerai is a San Francisco-based hedge fund and data science platform founded in 2015. Through a global competition and open API, thousands of data scientists submit stock market signals that are aggregated into a single Meta Model used to trade global equities. Numeraire (NMR) is used to stake and reward models that improve the fund. Numerai’s mission is to build the world’s last hedge fund through open, competitive machine intelligence.
Contact
Contact Numerai
contact@numer.ai
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ether.fi Partners with Nexus Mutual to Protect Against ETH Slashing at Institutional Scale
London, United Kingdom, July 17th, 2026, Chainwire
ether.fi, the leading onchain neobank for digital asset management, has selected Nexus Mutual to provide crypto’s largest-ever ETH Slashing Cover. The cover protects ether.fi‘s validators against up to 15,000 ETH worth of slashing penalties.
As ether.fi continues to see rapid adoption from both retail and institutional audiences, securing industry-leading protection against slashing risk for ether.fi users is critical. Over the last year, ether.fi has been systematically strengthening their stack across infrastructure, risk management, operational security and real-time defense systems.
Since ether.fi operates one of the largest validator sets on Ethereum, slashing is a real tail risk for them. By working with Nexus Mutual, ether.fi has mitigated this with protection that kicks in to secure against validator losses. This cover was calculated to protect ether.fi in even the most extreme scenarios and represents more than all historical losses from ETH slashing combined.
“We’ve always believed the safest protocols will ultimately win. That’s why we’ve invested heavily in audits, operational security, staking architecture, and now the largest insurance program in the industry. We are excited to partner with Nexus Mutual to make this a reality,” said Mike Silagadze, Founder & CEO of ether.fi.
“We’ve known the ether.fi team since before it was ether.fi, and they’ve been focused on risk from day one. Covering their users for up to 15,000 ETH in slashing penalties is a historic step, and we’re proud they chose Nexus Mutual to take it with them,” said Hugh Karp, Founder of Nexus Mutual.
About ether.fi
ether.fi is the leading onchain neobank for digital asset management. With $6B+ in AUM across Cash (crypto card), Stake (restaking), and Liquid (liquid restaking derivatives), ether.fi has established category dominance in crypto neobanking. It’s the rare institutional-grade product built for consumer adoption.
About Nexus Mutual
Nexus Mutual is the first crypto insurance alternative. Since 2019, they have covered more than $7 billion against smart contract hacks, slashing, and other digital asset risks. As the industry leader, they have become a trusted partner for everyone from individuals to institutions to help manage onchain risk.
Contact
Head of Marketing
Phil Johnston
Nexus Mutual
phil@nexusmutual.io
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Terrance Bradford Tampa, FL Explains Why Problem-Solving Is One of Construction’s Most Valuable Skills
Numerai Completes Third Strategic NMR Buyback, Bringing Total Repurchases to $3.2 Million
ether.fi Partners with Nexus Mutual to Protect Against ETH Slashing at Institutional Scale
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
JDLINO BRAND & FELITWO Celebrating El Champ — The Feroz Vargas and His Familión: A New Era in Boxing Power
-
Press Release1 week ago
Dubai Health and Rush University System for Health Announce Strategic Collaboration to Advance Quality of Care
-
Press Release1 week ago
SK Hynix ETFs – 2x Long (SKHX) & 1x Short (SKHZ) from Leverage Shares by Themes Arrive as ADRs Begin Trading
-
Press Release7 days ago
Thriving in Retirement Michael Masor’s Newly Released Book is a Complete Blueprint for Modern Retirement Planning
-
Press Release1 week ago
Ruckaroo Launches World’s First Fitness App Built for Weighted Walking
-
Press Release7 days ago
New Guide Helps Musicians Create a Connected Music Marketing System
-
Press Release4 days ago
Atlas Janitorial Services Delivers Professional Healthcare Facility Cleaning Solutions Across Houston
-
Press Release7 days ago
Northlake Concierge Medical Center Announces Boutique Class-A Medical Office Development in Tucker, Georgia